Cargando…

Nutritional and medical food therapies for diabetic retinopathy

Diabetic retinopathy (DR) is a form of microangiopathy. Reducing oxidative stress in the mitochondria and cell membranes decreases ischemic injury and end-organ damage to the retina. New approaches are needed, which reduce the risk and improve the outcomes of DR while complementing current therapeut...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Ce, Wang, Peng, Airen, Shriya, Brown, Craig, Liu, Zhiping, Townsend, Justin H., Wang, Jianhua, Jiang, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310218/
https://www.ncbi.nlm.nih.gov/pubmed/32582807
http://dx.doi.org/10.1186/s40662-020-00199-y
_version_ 1783549328201089024
author Shi, Ce
Wang, Peng
Airen, Shriya
Brown, Craig
Liu, Zhiping
Townsend, Justin H.
Wang, Jianhua
Jiang, Hong
author_facet Shi, Ce
Wang, Peng
Airen, Shriya
Brown, Craig
Liu, Zhiping
Townsend, Justin H.
Wang, Jianhua
Jiang, Hong
author_sort Shi, Ce
collection PubMed
description Diabetic retinopathy (DR) is a form of microangiopathy. Reducing oxidative stress in the mitochondria and cell membranes decreases ischemic injury and end-organ damage to the retina. New approaches are needed, which reduce the risk and improve the outcomes of DR while complementing current therapeutic approaches. Homocysteine (Hcy) elevation and oxidative stress are potential therapeutic targets in DR. Common genetic polymorphisms such as those of methylenetetrahydrofolate reductase (MTHFR), increase Hcy and DR risk and severity. Patients with DR have high incidences of deficiencies of crucial vitamins, minerals, and related compounds, which also lead to elevation of Hcy and oxidative stress. Addressing the effects of the MTHFR polymorphism and addressing comorbid deficiencies and insufficiencies reduce the impact and severity of the disease. This approach provides safe and simple strategies that support conventional care and improve outcomes. Suboptimal vitamin co-factor availability also impairs the release of neurotrophic and neuroprotective growth factors. Collectively, this accounts for variability in presentation and response of DR to conventional therapy. Fortunately, there are straightforward recommendations for addressing these issues and supporting traditional treatment plans. We have reviewed the literature for nutritional interventions that support conventional therapies to reduce disease risk and severity. Optimal combinations of vitamins B1, B2, B6, L-methylfolate, methylcobalamin (B12), C, D, natural vitamin E complex, lutein, zeaxanthin, alpha-lipoic acid, and n-acetylcysteine are identified for protecting the retina and choroid. Certain medical foods have been successfully used as therapy for retinopathy. Recommendations based on this review and our clinical experience are developed for clinicians to use to support conventional therapy for DR. DR from both type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) have similar retinal findings and responses to nutritional therapies.
format Online
Article
Text
id pubmed-7310218
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-73102182020-06-23 Nutritional and medical food therapies for diabetic retinopathy Shi, Ce Wang, Peng Airen, Shriya Brown, Craig Liu, Zhiping Townsend, Justin H. Wang, Jianhua Jiang, Hong Eye Vis (Lond) Review Diabetic retinopathy (DR) is a form of microangiopathy. Reducing oxidative stress in the mitochondria and cell membranes decreases ischemic injury and end-organ damage to the retina. New approaches are needed, which reduce the risk and improve the outcomes of DR while complementing current therapeutic approaches. Homocysteine (Hcy) elevation and oxidative stress are potential therapeutic targets in DR. Common genetic polymorphisms such as those of methylenetetrahydrofolate reductase (MTHFR), increase Hcy and DR risk and severity. Patients with DR have high incidences of deficiencies of crucial vitamins, minerals, and related compounds, which also lead to elevation of Hcy and oxidative stress. Addressing the effects of the MTHFR polymorphism and addressing comorbid deficiencies and insufficiencies reduce the impact and severity of the disease. This approach provides safe and simple strategies that support conventional care and improve outcomes. Suboptimal vitamin co-factor availability also impairs the release of neurotrophic and neuroprotective growth factors. Collectively, this accounts for variability in presentation and response of DR to conventional therapy. Fortunately, there are straightforward recommendations for addressing these issues and supporting traditional treatment plans. We have reviewed the literature for nutritional interventions that support conventional therapies to reduce disease risk and severity. Optimal combinations of vitamins B1, B2, B6, L-methylfolate, methylcobalamin (B12), C, D, natural vitamin E complex, lutein, zeaxanthin, alpha-lipoic acid, and n-acetylcysteine are identified for protecting the retina and choroid. Certain medical foods have been successfully used as therapy for retinopathy. Recommendations based on this review and our clinical experience are developed for clinicians to use to support conventional therapy for DR. DR from both type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) have similar retinal findings and responses to nutritional therapies. BioMed Central 2020-06-18 /pmc/articles/PMC7310218/ /pubmed/32582807 http://dx.doi.org/10.1186/s40662-020-00199-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Shi, Ce
Wang, Peng
Airen, Shriya
Brown, Craig
Liu, Zhiping
Townsend, Justin H.
Wang, Jianhua
Jiang, Hong
Nutritional and medical food therapies for diabetic retinopathy
title Nutritional and medical food therapies for diabetic retinopathy
title_full Nutritional and medical food therapies for diabetic retinopathy
title_fullStr Nutritional and medical food therapies for diabetic retinopathy
title_full_unstemmed Nutritional and medical food therapies for diabetic retinopathy
title_short Nutritional and medical food therapies for diabetic retinopathy
title_sort nutritional and medical food therapies for diabetic retinopathy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310218/
https://www.ncbi.nlm.nih.gov/pubmed/32582807
http://dx.doi.org/10.1186/s40662-020-00199-y
work_keys_str_mv AT shice nutritionalandmedicalfoodtherapiesfordiabeticretinopathy
AT wangpeng nutritionalandmedicalfoodtherapiesfordiabeticretinopathy
AT airenshriya nutritionalandmedicalfoodtherapiesfordiabeticretinopathy
AT browncraig nutritionalandmedicalfoodtherapiesfordiabeticretinopathy
AT liuzhiping nutritionalandmedicalfoodtherapiesfordiabeticretinopathy
AT townsendjustinh nutritionalandmedicalfoodtherapiesfordiabeticretinopathy
AT wangjianhua nutritionalandmedicalfoodtherapiesfordiabeticretinopathy
AT jianghong nutritionalandmedicalfoodtherapiesfordiabeticretinopathy